Product Portfolio - Ultragenyx Pharmaceutical Inc. has a diverse portfolio of approved therapies and product candidates targeting serious rare and ultra-rare genetic diseases [112]. - Crysvita is the only approved treatment for X-Linked Hypophosphatemia (XLH), with approximately 48,000 patients affected in the developed world [115]. - Mepsevii is approved for Mucopolysaccharidosis VII (MPS VII), affecting an estimated 200 patients in the developed world [118]. - Dojolvi is approved for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), with approximately 8,000 to 14,000 patients in the developed world [119]. - Evkeeza is approved for Homozygous Familial Hypercholesterolemia (HoFH), with around 3,000 to 5,000 patients in the developed world outside the U.S. [120]. - UX143 for Osteogenesis Imperfecta (OI) is in Phase 3, with final analysis expected around the end of 2025 [127]. - GTX-102 for Angelman Syndrome has enrolled 129 patients in the Phase 3 Aspire study, with data expected in the second half of 2026 [128]. - DTX401 for Glycogen Storage Disease Type Ia (GSDIa) achieved its primary endpoint in the Phase 3 GlucoGene study, showing significant reduction in daily cornstarch intake [131]. - UX111 for MPS IIIA received a Complete Response Letter from the FDA, with plans to resubmit the BLA in early 2026 [130]. Financial Performance - Total revenues increased by 15% to $159.9 million for the three months ended September 30, 2025, compared to $139.5 million in the same period of 2024 [139]. - Product sales increased by 23% to $94.993 million for the three months ended September 30, 2025, compared to $77.251 million in the same period of 2024 [141]. - Crysvita product sales increased by 32% to $47.003 million for the three months ended September 30, 2025, compared to $35.604 million in the same period of 2024 [141]. - The company incurred net losses of $180.4 million for the three months ended September 30, 2025, compared to $133.5 million for the same period in 2024 [137]. - Cash used in operating activities for the nine months ended September 30, 2025, was $366.2 million, reflecting a net loss of $446.4 million [166]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $83.8 million, a decrease from $396.1 million in the same period of 2024 [171]. Research and Development - Research and development expenses rose by 27% to $216.212 million for the three months ended September 30, 2025, compared to $170.109 million in the same period of 2024 [148]. - Total research and development expenses increased by $36.6 million (7%) for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to increases in gene therapy and biologic programs [149]. - The company expects annual research and development expenses to moderate as product candidates advance through clinical development [150]. Cash and Liquidity - As of September 30, 2025, the company had $447.3 million in available cash, cash equivalents, and marketable debt securities [139]. - Cash, cash equivalents, and marketable debt securities totaled $447.3 million as of September 30, 2025, down from $745.0 million as of December 31, 2024 [178]. - The company expects to satisfy future cash needs through existing capital balances and revenue from commercial products [174]. Future Outlook - The company anticipates continued annual losses in the near term due to ongoing product development and regulatory approvals [172]. - Future funding requirements will depend on various factors, including clinical study costs and regulatory interactions [173]. - A hypothetical 10% change in foreign exchange rates would not have had a material impact on the company's financial statements for the nine months ended September 30, 2025 [179]. Obligations and Expenses - Manufacturing and service contract obligations related to clinical stage pipeline amounted to approximately $125.4 million, with $92.9 million due within one year [176]. - As of September 30, 2025, future minimum lease payments under non-cancellable leases were approximately $40.3 million, with $15.1 million due within one year [175]. - Selling, general and administrative expenses rose by $21.9 million (9%) for the nine months ended September 30, 2025, driven by higher employee compensation and marketing expenses [153]. - Non-cash interest expense on liabilities for sales of future royalties decreased by $5.0 million (10%) for the nine months ended September 30, 2025, due to reduced royalty obligation balances [157]. - The provision for income taxes increased by $1.5 million (94%) for the nine months ended September 30, 2025, primarily due to increased foreign activities [160].

Financial Data and Key Metrics Changes - In Q3 2025, Ultragenyx reported total revenue of $160 million, representing a 15% increase compared to Q3 2024 and an 18% increase for the first nine months of 2025 over the same period in 2024 [14][15] - The net loss for the quarter was $180 million, equating to $1.81 per share [15] - As of September 30, 2025, the company had $447 million in cash, cash equivalents, and securities, bolstered by a recent $400 million financing [16] Business Line Data and Key Metrics Changes - Crysvita generated $112 million in revenue during Q3 2025, with contributions of $57 million from North America, $47 million from Latin America and Turkey, and $8 million from Europe [15] - Dojolvi contributed $24 million, maintaining steady growth, while Evkeeza and Mepsevii contributed $17 million and $7 million, respectively [15] - The company expects total revenue for 2025 to be between $640 million and $670 million, indicating a growth of 14% to 20% over 2024 [16][17] Market Data and Key Metrics Changes - In Latin America, approximately 875 patients are now on Crysvita therapy, with 50 new start forms generated in Q3 2025 [8] - Dojolvi has seen approximately 700 new start forms since its launch in 2020, leading to around 625 patients on reimbursed therapy, with a split of 65% pediatric and 35% adult patients [9] - Evkeeza has approximately 310 patients across 17 countries in the EMEA region, with 120 new patients added since the beginning of the year [10] Company Strategy and Development Direction - The company is focused on maximizing opportunities from its four commercial products and has two BLA submissions in progress for ultra-rare diseases [4] - Ultragenyx aims to maintain financial discipline while preparing for upcoming product launches and pivotal data readouts [14] - The company is positioned for growth with a strong balance sheet and plans to achieve profitability by 2027 [16][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming pivotal data readouts for GTX-102 and UX143, which are expected to be transformative for patients with Angelman syndrome and osteogenesis imperfecta [5][23] - The management team highlighted the importance of maintaining cash burn and prioritizing investments as they approach significant clinical milestones [5][16] - The company anticipates continued double-digit revenue growth from existing products and contributions from new launches [48] Other Important Information - The company received $400 million in non-dilutive capital through the sale of a portion of Crysvita royalties, with payments deferred until January 2028 [4][13] - The management team emphasized the unique value of Crysvita and its potential to deliver significant long-term value [14] Q&A Session Summary Question: Data update on Orbit and Cosmic studies - Management confirmed that data from both studies will be reported together, expected in December or January [27] Question: Open label extension from phase II for OI - Management stated that they have not released new quantitative data but are confident in the phase III expectations, aiming for a 40% to 70% reduction in fractures [31][32] Question: Clarification on UX111 and DTX401 submissions - Management explained that the timing of submissions was adjusted due to the need for additional reports, but both filings remain closely aligned [36] Question: Impact of OMERS transaction on financing needs - Management indicated that the $400 million raised will help address investor concerns regarding financing needs in 2026 and support upcoming product launches [42][48] Question: Length of treatment for Setrusumab - Management expressed confidence that Setrusumab will require chronic treatment to maintain bone health, suggesting bisphosphonates may become obsolete [70][73] Question: Loss of exclusivity for Setrusumab - Management highlighted the importance of orphan designation for exclusivity and mentioned ongoing patent protections that extend beyond 2030 [92]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported total revenue of $160 million, representing a 15% increase compared to Q3 2024 and an 18% increase for the first nine months of 2025 over the same period in 2024 [14][15] - The net loss for the quarter was $180 million, equating to $1.81 per share [15] - Cash, cash equivalents, and securities as of September 30, 2025, totaled $447 million, bolstered by a recent $400 million financing [16] Business Line Data and Key Metrics Changes - Crysvita generated $112 million in Q3 2025, with revenue contributions of $57 million from North America, $47 million from Latin America and Turkey, and $8 million from Europe [15] - DOJOLVI contributed $24 million, maintaining steady growth, while EVKEEZA and MEPSEVII contributed $17 million and $7 million, respectively [15] - The company expects total revenue for 2025 to be between $640 million and $670 million, indicating a growth of 14%-20% over 2024 [16] Market Data and Key Metrics Changes - In Latin America, approximately 875 patients are now on Crysvita therapy, with 50 new start forms generated in Q3 2025 [8] - In the EMEA region, around 310 patients are receiving EVKEEZA across 17 countries, with 120 new patients added since the beginning of the year [10] Company Strategy and Development Direction - The company is focused on maximizing opportunities from its four commercial products and has two BLA submissions in progress for ultra-rare diseases [4] - A recent $400 million financing through the sale of Crysvita royalties is aimed at strengthening the balance sheet and supporting upcoming pivotal data readouts [4][13] - The company plans to maintain financial discipline while preparing for the launch of new products and managing cash burn [5][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming pivotal data readouts for osteogenesis imperfecta and Angelman syndrome, with expectations for significant commercial opportunities [5][23] - The company reaffirmed its path to profitability by 2027, supported by continued double-digit growth from existing products and potential new launches [16][48] Other Important Information - The company is preparing for the rolling BLA submission for DTX401, expected to be completed next month, and anticipates a BLA resubmission for UX111 in early 2026 [18][21] - Management highlighted the importance of patient support programs in influencing treatment decisions among caregivers and patients [62] Q&A Session Summary Question: Data update on Orbit and Cosmic studies - Management confirmed that data from both studies will be reported together, expected in December or January, with variability in timing due to data cleaning processes [26][27] Question: Open label extension from phase II for OI - Management stated that while no new quantitative data is available, they are confident in the phase II results and expect a fracture reduction of 40%-70% in phase III [30][32] Question: Clarification on UX111 and DTX401 submissions - Management explained that the timing of submissions was adjusted due to the need for additional reports, with DTX401 expected to be filed first [35][36] Question: Impact of OMERS transaction on financing needs - Management indicated that the $400 million raised will help address investor concerns regarding financing needs in 2026, particularly related to priority vouchers [42][48] Question: Commercial opportunity for Setrusumab in OI - Management believes the OI population is larger than XLH and expects similar pricing, indicating a significant commercial opportunity [58] Question: Loss of exclusivity for Setrusumab - Management highlighted orphan designation as a protective factor against loss of exclusivity, with additional patents in place to extend protection [90]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported total revenue of $160 million, representing a 15% increase compared to Q3 2024 and an 18% increase for the first nine months of 2025 over the same period in 2024 [13][14] - The net loss for the quarter was $180 million, equating to $1.81 per share [15] - As of September 30, 2025, the company had $447 million in cash, cash equivalents, and securities, bolstered by a recent $400 million financing [16] Business Line Data and Key Metrics Changes - Crysvita generated $112 million in revenue during Q3 2025, with contributions of $57 million from North America, $47 million from Latin America and Turkey, and $8 million from Europe [14] - Dojolvi contributed $24 million, maintaining steady growth, while Evkeeza and Mepsevii contributed $17 million and $7 million, respectively [14] - The company expects total revenue for 2025 to be between $640 million and $670 million, indicating a growth of 14% to 20% over 2024 [16] Market Data and Key Metrics Changes - In Latin America, the company added approximately 50 new patients on reimbursed therapy for Crysvita, bringing the total to around 875 patients [8] - In the EMEA region, Evkeeza has approximately 310 patients receiving treatment across 17 countries, with 120 new patients added since the beginning of the year [10] Company Strategy and Development Direction - The company is focused on maximizing opportunities from its four commercial products and has two BLA submissions in progress for ultra-rare diseases [3] - A recent $400 million financing through the sale of a portion of Crysvita royalties is aimed at strengthening the balance sheet and supporting upcoming pivotal data readouts [3][12] - The company plans to maintain financial discipline while preparing for the launch of new products and managing cash burn [4][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming pivotal data readouts for GTX-102 and UX143, which are expected to be transformative for patients with Angelman syndrome and osteogenesis imperfecta [4][23] - The company reaffirmed its path to profitability by 2027, supported by expected double-digit growth from existing products and new launches [12][48] Other Important Information - The company is preparing for a rolling BLA submission for DTX401, with expectations to complete this filing in December [23] - Management highlighted the importance of patient support programs in ensuring access to treatments, especially in a competitive landscape for Angelman syndrome therapies [64] Q&A Session Summary Question: Data update on Orbit and Cosmic studies - Management confirmed that data from both studies will be reported together, expected in December or January [26][27] Question: Open label extension from phase II for OI - Management stated that while no new quantitative data is available, they are confident in the phase III expectations, anticipating a fracture reduction of 40% to 70% [30][32] Question: Clarification on UX111 and DTX401 submissions - Management explained that the timing of submissions was adjusted due to the need for additional reports, but both filings remain closely timed [36][38] Question: Impact of OMERS transaction on financing needs - Management indicated that the recent financing strengthens the balance sheet and supports the path to profitability in 2027 [44][48] Question: Length of treatment for Setrusumab - Management expressed confidence that Setrusumab will require chronic treatment to maintain bone health, suggesting bisphosphonates may become obsolete [72][74] Question: Loss of exclusivity for Setrusumab - Management highlighted orphan designation and additional IP protections that extend exclusivity beyond 2030 [98][99]

Revenue Performance - Total revenue for Q3 2025 was $160 million, representing a 15% growth compared to Q3 2024[4] - Crysvita revenue in Q3 2025 was $112 million, including $47 million from Latin America and Türkiye[4] - Dojolvi revenue in Q3 2025 was $24 million[4] - Total revenues for Q3 2025 reached $159.933 million, a 14.7% increase from $139.494 million in Q3 2024[30] - Product sales increased to $94.993 million in Q3 2025, up from $77.251 million in Q3 2024, representing a 22.9% growth[30] - Royalty revenue for Q3 2025 was $64.940 million, compared to $62.243 million in Q3 2024, showing a 4.3% increase[30] Financial Guidance - The company reaffirmed 2025 revenue guidance of $640 million to $670 million, with Crysvita revenue expected between $460 million to $480 million[13] Operating Expenses - Operating expenses for Q3 2025 totaled $331 million, including $37 million in non-cash stock-based compensation[5] - Operating expenses totaled $330.823 million in Q3 2025, a 21.8% increase from $271.481 million in Q3 2024[30] - Research and development expenses rose to $216.212 million in Q3 2025, up from $170.109 million in Q3 2024, reflecting a 27.1% increase[30] Net Loss - Net loss for Q3 2025 was $180 million, or $1.81 per share, compared to a net loss of $134 million, or $1.40 per share in Q3 2024[7] - Net loss for Q3 2025 was $180.413 million, compared to a net loss of $133.516 million in Q3 2024, indicating a 35.1% increase in losses[30] - Net loss per share for Q3 2025 was $1.81, compared to $1.40 in Q3 2024[30] Cash and Assets - Cash, cash equivalents, and marketable debt securities were $447 million as of September 30, 2025[8] - Cash, cash equivalents, and marketable debt securities decreased to $447.315 million as of September 30, 2025, down from $745.029 million at the end of 2024[34] - Total assets as of September 30, 2025, were $1.190 billion, a decrease from $1.503 billion at the end of 2024[34] - Total stockholders' equity fell to $9.159 million as of September 30, 2025, down from $255.297 million at the end of 2024[34] Future Developments - UX143 for osteogenesis imperfecta is expected to have phase 3 study readouts by the end of 2025[12] - The company plans to resubmit the BLA for UX111 early in 2026 following constructive discussions with the FDA[16] Balance Sheet Improvement - The company received $400 million from the sale of a portion of its Crysvita royalty interest, enhancing its balance sheet[9]

Core Insights - Ultragenyx Pharmaceutical Inc. reported total revenue of $160 million for Q3 2025, marking a 15% increase compared to Q3 2024 [4][5][11] - The company reaffirmed its 2025 revenue guidance, expecting total revenue between $640 million to $670 million, with Crysvita revenue projected at $460 million to $480 million and Dojolvi revenue between $90 million to $100 million [1][16] - A significant balance sheet improvement was noted with $400 million raised from the sale of a portion of Crysvita royalty interest [1][9] Financial Performance - Total revenues for Q3 2025 were $159.9 million, up from $139.5 million in Q3 2024 [5][30] - Crysvita revenue for Q3 2025 was $112 million, including $47 million from Latin America and Türkiye [4][30] - Dojolvi generated $24 million in revenue during the same period [4][30] - Operating expenses totaled $331 million for Q3 2025, which included $37 million in non-cash stock-based compensation [6][30] - The net loss for Q3 2025 was $180 million, or $1.81 per share, compared to a net loss of $134 million, or $1.40 per share, in Q3 2024 [7][30] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and marketable debt securities amounting to $447 million [8][35] - Net cash used in operations for Q3 2025 was $91 million, with a total of $366 million used in the first nine months of 2025 [10][11] Clinical Developments - The company is preparing for pivotal milestones in its late-stage clinical pipeline, including the Phase 3 study readouts for UX143 in osteogenesis imperfecta expected by the end of 2025 [2][12] - Enrollment for the Phase 3 Aspire study of GTX-102 for Angelman syndrome has been completed, with data expected in the second half of 2026 [13] - The company plans to resubmit the Biologics License Application (BLA) for UX111 early in 2026 [15][18] Strategic Updates - The company has engaged in discussions with the FDA following a Complete Response Letter (CRL) and plans to include additional clinical data in the BLA resubmission [17][18] - The rolling submission of the BLA for DTX401 is expected to be completed in Q4 2025, with significant data supporting its efficacy [19][20]

Core Insights - Ultragenyx Pharmaceutical Inc. has sold an additional 25% of its royalty interest in Crysvita® for $400 million to OMERS, a major Canadian pension plan, which will begin receiving this royalty in January 2028 [1][2] - The proceeds from this transaction will support four expected product launches and contribute to the company's growth strategy, aiming for full-year GAAP profitability by 2027 [2] - Crysvita® has generated over $4 billion in cumulative sales in the U.S. and Canada, treating more than 3,000 patients since its launch [2] Financial Details - The new agreement with OMERS caps total payments at 1.55 times the purchase price, following a previous agreement that capped payments at 1.45 times [1] - OMERS will continue to receive 30% of Crysvita® net sales in the U.S. and Canada after the previous agreement's cap is reached [1] Company Background - Ultragenyx is focused on developing therapies for serious rare and ultra-rare genetic diseases, with a diverse portfolio of approved medicines and treatment candidates [4][5] - The company has a management team experienced in rare disease therapeutics and emphasizes efficient drug development [5] Partnership Insights - OMERS Life Sciences specializes in providing royalty financing and non-dilutive solutions to biopharma companies, aligning with its strategy of delivering steady, long-term returns to its members [6][7] - The partnership with Ultragenyx reflects OMERS' commitment to investing in the life sciences sector and supporting innovative treatments for rare diseases [2][6]

Core Insights - Kiora Pharmaceuticals has joined the Global Genes' RARE-X Vision Consortium to enhance collaboration in developing therapies for rare ocular disorders [1][3][9] Group 1: Consortium Objectives - The RARE-X Vision Consortium aims to facilitate collaboration among advocacy, research, and industry stakeholders to advance research for vision-improving therapies [1][2] - The consortium will create a global, centralized data repository to aid in patient identification and recruitment for clinical trials [4] - It seeks to develop meaningful outcome measures for clinical trials by aggregating various data types to identify endpoints that correlate with significant vision changes [4] Group 2: Kiora Pharmaceuticals' Role - Kiora is focused on developing innovative treatments for inherited retinal diseases, including KIO-301 and KIO-104, which target critical pathways to slow or restore vision loss [7] - The company emphasizes the importance of collaboration to accelerate the development of new therapies for rare ocular diseases [3][7] Group 3: Stakeholder Engagement - The Vision Consortium includes various patient advocacy groups, enhancing the representation of diverse perspectives in clinical trial design [4][5] - Kiora's involvement is expected to strengthen the consortium's efforts in addressing the challenges of drug development in the rare disease space [3][9]

Core Insights - Ultragenyx Pharmaceutical Inc. has initiated the Aurora study to evaluate the efficacy and safety of GTX-102 (apazunersen) for Angelman syndrome, expanding the patient population to include younger and older patients as well as those with non-deletion AS genotypes [1][2] - The Aurora study aims to enroll approximately 60 participants aged 1 to under 65, with a focus on diverse genotypes and age groups, reflecting a commitment to inclusivity in clinical trials [2][3] - GTX-102 has received multiple designations from the FDA and EMA, indicating its potential as a breakthrough therapy for Angelman syndrome, a rare neurogenetic disorder affecting around 60,000 individuals [4][6] Company Overview - Ultragenyx is a biopharmaceutical company dedicated to developing therapies for rare and ultra-rare genetic diseases, with a portfolio aimed at addressing high unmet medical needs [8] - The company emphasizes efficient drug development processes to deliver safe and effective therapies urgently [9] Study Design and Objectives - The Aurora study features an open-label basket design, allowing for the evaluation of GTX-102 across different age groups and genotypes [2] - Participants will be divided into four cohorts, each with specific age ranges and genotypes, focusing on various primary endpoints related to cognitive and response measures [2] - The study includes a 48-week primary efficacy period, with a crossover option for the No Treatment group to receive GTX-102 after 24 weeks [2] Background on Angelman Syndrome - Angelman syndrome is characterized by cognitive and motor impairments, seizures, and requires continuous care, affecting individuals' quality of life [7] - The disorder is caused by the loss of function of the maternally inherited UBE3A gene, with no currently approved therapies available [5][7]

Core Insights - Ultragenyx Pharmaceutical Inc. will host a conference call on November 4, 2025, to discuss its financial results and corporate updates for Q3 2025 [1] - The call will be accessible via the company's website, with a replay available for three months [2] Company Overview - Ultragenyx is a biopharmaceutical company focused on developing and commercializing novel products for serious rare and ultra-rare genetic diseases [3] - The company has a diverse portfolio of approved therapies and product candidates targeting diseases with high unmet medical needs [3] - Ultragenyx's management team has extensive experience in the development and commercialization of therapeutics for rare diseases [4] - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies urgently [4]